<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the efficacy and safety of high-dose intravenous <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> (1 g x 3 days) pulse therapy followed in the management of <z:hpo ids='HP_0011009'>acute</z:hpo> posterior segment <z:hpo ids='HP_0000554'>uveitis</z:hpo> attacks in 25 patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease </plain></SENT>
<SENT sid="1" pm="."><plain>High-dose intravenous <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> pulse therapy may be beneficial in the prompt control of severe <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> and in preventing <z:hpo ids='HP_0000572'>visual loss</z:hpo> </plain></SENT>
</text></document>